Document:

Letter dated August 8, 2002 from Axel Johnson

  
 Exhibit 10.1 
  
 August 8, 2002 
  
 Larscom Incorporated 
 1845 McCandless Drive 
 Milpitas, CA 95035 
  
 Gentlemen: 
  
 We write in connection with that certain Credit Agreement dated as of December 24, 1996 (the “Credit
Agreement”) by and between Axel Johnson Inc. (“Axel Johnson”) and Larscom Incorporated (“Larscom”), as amended. 
  
 The Credit Agreement provides that Larscom may effect a borrowing under the Credit Agreement only if certain conditions are met as of the time of such borrowing. These conditions include, inter alia, the conditions set
forth in Sections 5(d) and 6(a) of the Credit Agreement, that as of the time of any borrowing, no material adverse change shall have occurred in the financial condition or the results of operations of Larscom since November 20, 1998 (the “No
MAC Condition”). 
  
 At the request of Larscom, Axel Johnson hereby confirms the following: (i) Axel Johnson is aware that Larscom has
experienced adverse financial results in recent periods relative to historical financial performance; (ii) it is and remains the intent of Axel Johnson that Larscom may undertake borrowings under the Credit Facility, notwithstanding those financial
results, provided Larscom does not experience any material and adverse change in its financial condition or results of operations subsequent to the date hereof. 
  
 Accordingly, at the request of Larscom, and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Axel Johnson agrees to waive the No MAC Condition with respect to the financial
condition and the results of operations of Larscom as of the date hereof. 
  
 Larscom shall be entitled to rely upon this waiver and
confirmation in considering the availability of borrowings under the Credit Agreement and reporting the same in Larscom’s publicly filed reports. 
  
 Very truly yours, 
  
 AXEL JOHNSON INC. 
  
 /s/    CHARLES E. MURPHY 
  
 Charles E.
Murphy 
 Vice President and Treasurer<PAGE>

Confidential treatment has been requested by OraPharma, Inc. pursuant to Rule
24b-2. All non-public information has been filed with the Securities and
Exchange Commission.

                                                                   Exhibit 10.16

                             DISTRIBUTION AGREEMENT

This AGREEMENT (the "Agreement") dated as of August 19, 2002 (the "Effective
Date") between Kensey Nash Corporation, a Delaware corporation, having its
principal place of business at 55 East Uwchlan Avenue, Exton, PA 19341
(hereinafter referred to as "KNC") and OraPharma, Inc, a Delaware corporation,
having its principal place of business at 732 Louis Drive, Warminster, PA 18974
(hereinafter referred to as "OraPharma").

Whereas, KNC develops, manufactures and sells for consideration medical devices
fabricated from bioresorbable materials into anatomically or functionally
specific three-dimensional architectures whose functional talents can be applied
to hard and soft-tissue wound healing. This technology employs proprietary
manufacturing processes that produce varieties of polymer architectures designed
for specific wound model and tissue engineering applications.

Whereas, OraPharma is a company engaged in the development, manufacture and
marketing of specialty pharmaceutical products related to the treatment of
periodontal disease.

Whereas, KNC has received Section 510(k) clearance from the U.S. Food and Drug
Administration to market Epi-Guide(R) bioresorbable periodontal matrix barrier
in the U.S. in accordance with the provisions of the U.S. Federal Food, Drug and
Cosmetic Act, and is presently marketing the Epi-Guide(R) product in the United
States.

Whereas, KNC has received pre-market approval from the U.S. Food and Drug
Administration to market Drilac(R) surgical dressing in the U.S. in accordance
with the provisions of the U.S. Federal Food, Drug and Cosmetic Act, and is
presently marketing the Drilac(R) product in the United States.

Whereas both the Epi-Guide(R) product and the Drilac(R) product have received
regulatory approval to be marketed and sold in Canada, and KNC is presently
marketing both products in Canada.

Whereas, OraPharma desires to advertise, promote, market, distribute and sell
Product (as defined below) for exclusive use in the Field (as defined below) in
the Territory (as defined below).

Whereas, KNC is willing, for the consideration and on the terms set forth
herein, to grant the distribution right, as defined below, to OraPharma for such
purposes.

         Now, therefore, in consideration of the mutual covenants and promises
contained in this Agreement and other good and valuable consideration, KNC and
OraPharma agree as follows:

                                 1. DEFINITIONS

         1.1.  "Confidential Information" shall mean all oral or written
               information that is marked as "Confidential", that is disclosed
               by either party (the "Disclosing Party") to the other party (the
               "Receiving Party") that is not generally known to the public,
               including but not limited to, information of a technical nature
               such as trade secrets; manufacturing processes or devices;
               techniques, data, formulas, inventions (whether or not
               patentable), specifications and characteristics of current
               products or products under development; research projects,
               methods and results; matters of a business nature such as
               information about costs, margins, pricing policies, markets,
               sales, suppliers and customers; product, marketing or strategic
               plans; financial information; personnel records and other
               information of a similar nature, provided, however, that
               Confidential

<PAGE>

               Information shall not include any information that (i) is or
               becomes public knowledge without breach of the Receiving Party's
               obligations hereunder; (ii) is rightfully acquired by the
               Receiving Party from a third party without restriction on
               disclosure or use; (iii) was already known to Receiving Party
               prior to receipt from the Disclosing Party; (iv) was or is
               disclosed by the Disclosing Party to a third party prior to or
               after the date of this Agreement without restriction on
               disclosure or use; or (v) is disclosed or used following the
               Receiving Party's receipt of express written consent from a
               representative of the Disclosing Party. The Receiving Party shall
               have the burden of proof respecting any of the aforementioned
               events on which the Receiving Party relies as relieving it of any
               restrictions. Oral disclosures for which protection is sought
               must at the outset be clearly identified by the Disclosing Party
               as Confidential Information and submitted by the Disclosing Party
               to the Receiving Party, marked as above within thirty (30) days
               after disclosure.

         1.2.  "Field" shall mean the dental profession.

         1.3.  "Minimum Purchase Guarantee" shall have the meaning set forth in
               Section 4.2.

         1.4.  "Product" or "Products" shall mean either one or more of the
               devices meeting the specifications set forth in Schedule A
               ("Product Specifications") and Schedule B ("Product Drawings"),
               which are attached hereto and made part of this Agreement. Such
               specifications may be changed from time to time only as agreed to
               in writing by the parties. Product shall be labeled for use in
               the Field, and solely labeled as such with no alternate
               indications for use. Product shall include any improvements,
               modifications or replacements thereof, as made commercially
               available by KNC in any market anywhere in the world.

         1.5.  "Sub-distributor" shall mean any entity designated by OraPharma
               to advertise, promote, market, distribute and sell the Product
               within a certain geographic area of the Territory where OraPharma
               reasonably believes that circumstances require the appointment of
               a Sub-distributor.

         1.6.  "Territory" shall mean the United States of America and Canada.

                         2. DISTRIBUTION GRANT AND TERM

         2.1.  Subject to Section 2.2 and the reservation of rights set forth in
               Section 2.3 of this Agreement, KNC hereby grants to OraPharma an
               exclusive (even as to KNC) distribution right to the Product for
               the sole and exclusive purpose of advertising, promoting,
               marketing, distributing and selling Product in the Field in the
               Territory during the Term. The exclusive distribution right
               granted herein shall terminate upon termination or expiration of
               this Agreement in accordance with Section 2.6 or Section 15
               hereof.

         2.2   Until receipt of written notification from OraPharma of its
               intention to fill customer orders, KNC shall continue to service
               existing and new customer orders for the Product.

                                        2

<PAGE>

         2.3.  Notwithstanding the distribution rights granted in Section 2.1,
               KNC does not convey manufacturing rights to the Product to
               OraPharma and OraPharma will exclusively purchase the Product
               from KNC during the Term of the Agreement.

         2.4.  OraPharma may use Sub-distributors (each, a "Sub-distributor"),
               provided that, the sub-distribution agreement must be at least as
               restrictive as this Agreement with respect to the rights and
               obligations of the Sub-distributors. OraPharma shall be
               responsible for monitoring Sub-distributors, so that the terms of
               this Agreement are met. OraPharma shall be liable to KNC in the
               event that a Sub-distributor causes a material breach of any
               provision of this Agreement. OraPharma shall provide prior
               written notice of its intention to use a particular
               Sub-distributor to KNC, and KNC shall have ten (10) business days
               to make any reasonable business objection.

         2.5.  During the Term of this Agreement, OraPharma shall not sell
               Product outside the Territory or sell Product to any person who,
               to the best of OraPharma's knowledge, intends to resell or reship
               them outside of the Territory. OraPharma agrees to refer to KNC
               all inquiries received by OraPharma for the sale of Product or
               reshipment of Product outside of the Territory.

         2.6.  This Agreement shall commence on the Effective Date and continue
               until September 30, 2007 (the "Initial Term"). The Agreement
               shall be renewed automatically for two successive five (5) year
               terms (the "Extended Term"), with the pricing to be renegotiated;
               provided however that new Minimum Purchase Guarantee shall be set
               at the greater of (a) an average of actual purchases by OraPharma
               over the last two years of the preceding term and (b) the Minimum
               Purchase Guarantee during year 5 of the previous term, and shall
               not change for the duration of that Extended Term. (As defined by
               this Section 2.6, the Initial Term, the Extended Term and any
               extensions thereon are herein collectively referred to as
               "Term"). Upon completion of the fourth contract year of the
               Initial Term, and at any time thereafter, either Party may give
               notice of its intention to terminate the Agreement or,
               alternatively, to remove Product or Products from Schedule A
               ("Termination Notice"). Such Termination Notice shall be written
               and a minimum of two (2) years prior to the desired termination.

                         3. COMMERCIALIZATION AND SUPPLY

         3.1.  KNC agrees to:

               (a)  use commercially reasonable efforts to supply OraPharma with
                    OraPharma's projected requirements (pursuant to Subsection
                    3.2(i)) of Product;

               (b)  supply OraPharma with Product manufactured in material
                    compliance with FDA device applications for Epi-Guide and
                    Drilac and FDA Quality System Regulations, ISO 9001:1994, EN
                    46001:1994, and ISO 13485.

               (c)  supply OraPharma with fifty percent (50%) of OraPharma's
                    year one Minimum Purchase Guarantee of Product as set forth
                    on Schedule C hereof as soon as practical following the
                    execution of this Agreement;

                                        3

<PAGE>

               (d)  provide OraPharma with [***] units of Epi-Guide(R) Product,
                    marked as "sample," at no cost to OraPharma, [***] to be
                    provided with the initial delivery of Product and the
                    balance delivered with the next purchase order;

               (e)  provide OraPharma with all current customer lists, packaging
                    material, package inserts, sales materials, and other
                    relevant information relating to the Product to enable the
                    transfer to OraPharma of KNC's current sales base for the
                    Product;

               (f)  following the written notification provided for in Section
                    2.2, promptly inform OraPharma of and refer to OraPharma any
                    orders for Product in the Territory it may receive from any
                    person or entity not affiliated with OraPharma;

               (g)  allow OraPharma to use, free of charge, any and all artwork
                    and/or marketing aids and materials developed by KNC and
                    associated with the Product;

               (h)  promptly provide OraPharma with relevant information,
                    including correspondence from US FDA, concerning adverse
                    reactions to the Product and safety information in
                    accordance with US FDA medical device reporting requirements
                    and keep accurate records of the same. KNC will be
                    responsible for all reporting to the FDA in compliance with
                    medical device reporting requirements (21 CFR Part 803);

               (i)  promptly notify OraPharma in writing of any changes to the
                    Product Specifications set forth in Schedule A; and

               (j)  provide a mutually acceptable link to OraPharma's website
                    from the website KNC maintains for each Product, at least as
                    prominent as links maintained to any other Product
                    distributor, and allow OraPharma to link its website to the
                    Product websites.

         3.2.  OraPharma agrees to:

               (a)  use commercially reasonable best efforts, consistent with
                    efforts for its internally developed products, to promote
                    and market the Product in the Territory;

               (b)  market and sell the Product in the Field only for the
                    indication approved on the Product labeling;

               (c)  be solely responsible for the cost and implementation of all
                    marketing, sales, promotional and related activities
                    concerning the marketing, sale and promotion of the Product
                    in the Territory;

               (d)  design and provide to KNC all product inserts, advertising,
                    promoting and marketing aids to be packaged with Product
                    that vary from the specifications set forth in Schedule B;

[***] Confidential treatment requested

                                        4

<PAGE>

               (e)  be solely responsible for the cost of any packaging redesign
                    (e.g., artwork, labeling, configurations), which varies from
                    the Product Drawings set forth in Schedule B. OraPharma will
                    provide at its expense, or reimburse KNC for, any inventory
                    requirements of packaging materials. If a packaging redesign
                    results in material and labor costs either higher or lower
                    from what is anticipated in Product Drawings set forth in
                    Schedule B, transfer prices of Product shall be adjusted
                    accordingly;

               (f)  include reference to KNC's role as the developer and
                    manufacturer of the Product on all packaging, marketing,
                    sales and instructional materials in a manner acceptable to,
                    or as specified by KNC, such approval not to be unreasonably
                    withheld;

               (g)  prior to use, provide copies to KNC of all marketing,
                    instructional and other materials which include reference to
                    the Product, its image, name or logo which may be developed
                    by OraPharma and intended to be used to market to the end
                    use customer for KNC's approval, which shall not be
                    unreasonably withheld or delayed. Such materials may
                    include, but are not limited to, packaging materials and
                    inserts, brochures, direct mailings, trade show visuals and
                    web content;

               (h)  consult and cooperate with KNC in the creation of
                    instructional materials to enable the customers of OraPharma
                    to use the Product safely and as intended;

               (i)  provide KNC with non-binding twelve (12) month forecasts of
                    OraPharma's requirements of Product. Such forecasts shall be
                    prepared in good faith and provided at the commencement of
                    the Agreement and on a quarterly basis, no less than thirty
                    (30) days prior to the beginning of each calendar quarter.
                    OraPharma shall have no liability hereunder for errors in
                    its forecasts. It is understood that KNC is not required to
                    produce Product inventory in excess of the forecasts,
                    therefore, OraPharma will commit to carry a reasonable level
                    of inventory to allow for normal fluctuations in sales
                    demand so as to allow KNC reasonable lead time to meet any
                    change in demand;

               (j)  maintain a fully qualified and effective sales organization,
                    including sufficiently adequately trained, experienced and
                    competent personnel to perform and discharge OraPharma's
                    obligations hereunder;

               (k)  develop and maintain an accurate and timely customer
                    complaint reporting system for the Product meeting the FDA
                    medical device reporting requirements (21 CFR Part 803). Any
                    reports generated by the system referred to in this
                    Subsection 3.2(k) should be forwarded to KNC as soon as
                    reasonably practical and in no event later than three (3)
                    business days following the notification of the event;

               (l)  promptly notify KNC in writing of any possible infringement
                    by any third party of any trademark, trade name or other
                    intellectual property right of KNC of which OraPharma
                    becomes aware, as well as any claim of infringement of any

                                        5

<PAGE>

                    intellectual property right against KNC or OraPharma as the
                    result of any of OraPharma's actions pursuant to this
                    Agreement; and

               (m)  at all times conduct its business in a manner as will
                    reflect favorably on KNC and the Product and will not engage
                    in any deceptive, misleading, illegal, or unethical business
                    practices.

                              4. PRICE AND PAYMENTS

         4.1.  Transfer prices for the Product shall be set during the Initial
               Term of the Agreement as follows, wherein a unit comprises an
               individual Epi-Guide:

               Annual Total Units Purchased         Transfer Price Per Unit($US)
               ----------------------------         ----------------------------

               [***]                                [***]

               Transfer prices for Drilac syringes will be [***] for a box of 12
               syringes or [***] for a box of 10 cubes, regardless of purchase
               quantity.

         4.2.  OraPharma agrees to purchase minimum annual quantities of
               Epi-Guide Product (the "Minimum Purchase Guarantee") throughout
               the Term of the Agreement. [***] The Minimum Purchase Guarantees
               for the Initial Term are set forth on Schedule C. If OraPharma
               fails to purchase the Minimum Purchase Guarantee, KNC will have
               the right, at its discretion, to downgrade the Agreement to a
               non-exclusive agreement or to terminate the Agreement, in either
               case by thirty (30) day's written notice to OraPharma.

         4.3.  KNC shall use commercially reasonable efforts to supply OraPharma
               with its requirements of Product and will promptly notify
               OraPharma of a shortage of supply of Product. In the event that
               KNC is unable to ship the Minimum Purchase Guarantee of Product
               to OraPharma in any year, the Minimum Purchase Guarantee for the
               year in which the shortage of supply occurs shall be waived and
               OraPharma will only be responsible for payment on actual Product
               shipped by KNC. KNC shall not be liable for any damages (actual,
               indirect, or consequential) of OraPharma arising from a shortage
               of supply of Product.

         4.4.  KNC shall ship Product to the location(s) designated by OraPharma
               F.O.B. Exton, Pennsylvania. OraPharma shall pay the actual
               documented cost of shipping Product to OraPharma facilities.
               OraPharma shall be responsible for all insurance, custom charges
               and taxes related to shipping and the distribution of the
               Product.

         4.5.  KNC shall invoice (net 30 day terms) OraPharma for the aggregate
               Product shipments and OraPharma shall pay each invoice within
               such thirty (30) day period.

         4.6.  All payments due pursuant to this Agreement shall be paid by wire
               transfer to a bank account specified by KNC in United States
               Dollars.

[***] Confidential treatment requested

                                        6

<PAGE>

        5. INSPECTION AND DISPUTE RESOLUTION RELATING TO SATISFACTION OF
                             PRODUCT SPECIFICATIONS

         5.1.  Inspection. Each shipment of Product shall be accompanied by a
               certificate of conformance for the production batch. OraPharma,
               or a designate acceptable to KNC, shall inspect and analyze each
               shipment of Product delivered by KNC and any claims regarding
               quantity or quality of same shall be made by OraPharma in writing
               to KNC specifying in reasonable detail the nature and basis for
               the claim and citing relevant control numbers or other
               information to enable specific identification of Product in
               question.

         5.2.  If a shipment is deficient in quality or quantity, KNC shall
               promptly make up or replace the affected quantity of Product at
               its expense, including cost of shipping and import. OraPharma
               shall, at KNC's expense and direction, dispose of any defective
               Product.

         5.3.  Resolution of Disputes Relating to Product Specifications. If the
               parties hereto fail to agree as to whether a delivered quantity
               of Product meets its agreed specifications, then the parties
               shall cooperate to have the Product in dispute analyzed by a
               qualified independent testing laboratory selected by KNC to which
               OraPharma does not have reasonable objection. The following
               provisions shall apply with respect to the results indicated by
               such independent laboratory:

               (a)  If the Product is determined to have met its specifications,
                    then OraPharma shall bear the costs of the independent
                    laboratory testing and shall accept the shipment of such
                    Product.

               (b)  If the Product is determined not to meet its specifications,
                    then KNC promptly shall replace the affected quantity as
                    outlined in Section 5.2 and KNC shall bear the costs of the
                    independent laboratory testing.

                            6. REPORTING REQUIREMENTS

         6.1.  OraPharma shall deliver to KNC within twenty (20) days after the
               end of each calendar quarter a written report showing its unit
               and dollar sales for such calendar quarter for the Product. All
               unit and dollar sales shall be segmented in each report according
               to sales by OraPharma and each Sub-distributor, by Product, as
               well as on a country-by-country basis. For purposes hereof, all
               monetary units shall be in United States Dollars.

         6.2.  OraPharma shall keep and maintain complete and accurate records
               relating to this Agreement, including records that ensure KNC's
               ability to perform a complete lot history via lot tracing of
               Product, and the reports required by this Article 6. Such records
               shall be maintained by OraPharma for a period of five (5) years
               from the date of any commercial transaction related to this
               Agreement. OraPharma shall, upon reasonable prior written notice
               from KNC, allow KNC to inspect such records.

                         7. INTELLECTUAL PROPERTY RIGHTS

                                        7

<PAGE>

         7.1.  Except as specifically set forth herein, KNC owns and shall
               continue to own entire right, title and interest in and to the
               Product and intellectual property relating thereto.

         7.2.  Product Marks:

               (a)  After the written consent of KNC, which shall be promptly
                    given and shall not be unreasonably refused, OraPharma and
                    its Sub-distributors shall have the right to develop and use
                    during the Term all trademarks or trade names developed by
                    OraPharma (collectively, "OraPharma Marks") in connection
                    with the marketing, distribution and sale of the Product and
                    will be the sole and exclusive owner of any such OraPharma
                    Marks and the goodwill pertaining thereto;

               (b)  OraPharma shall have a limited license to use the trademark
                    Epi-Guide(R), Drilac(R), and "OPLA" ("Marks") in connection
                    with the Product during the Term of this Agreement only to
                    the extent necessary to effect the terms of this Agreement.
                    KNC shall continue to be the sole and exclusive owner of the
                    Marks;

               (c)  Other than as set forth in Subsection 7.2(b) above,
                    OraPharma shall not use the Marks in any manner without
                    KNC's prior written consent. When using any of KNC's or
                    OraPharma's Marks, OraPharma shall comply with all
                    applicable laws and regulations relating to the use of
                    trademarks or trade names; and

               (d)  KNC and OraPharma acknowledge the exclusive right, title,
                    interest and goodwill in and to each trademark, trade name
                    or other intellectual property right owned by the other
                    party. Neither KNC nor OraPharma will, at any time or in any
                    way, do or cause to be done any act, or omission, or thing
                    to challenge, contest or in any way impair the right, title,
                    and interest of the other party. Except as otherwise
                    provided in this Agreement, KNC and OraPharma shall not in
                    any manner represent that either has any rights in or to any
                    trademark, trade name or other intellectual property right
                    of the other party and each acknowledges that the permitted
                    use of any trademark, trade name or other intellectual
                    property right of the other shall not create any ownership
                    right, title, or interest in or to any trademark, trade name
                    or other intellectual property right of the other party.

                           8. CONFIDENTIAL INFORMATION

         8.1.  The parties agree:

               (a)  To receive and hold all Confidential Information in strict
                    confidence and to disclose such Confidential Information
                    only to its employees and representatives who have a need to
                    know the Confidential Information. Without affecting the
                    generality of the foregoing, the Receiving Party will
                    exercise no less care to safeguard the Confidential
                    Information than it exercises in safeguarding its own
                    Confidential Information and will be responsible for any
                    breach of the provisions of Article 8 by its employees and
                    representatives

                                        8

<PAGE>

                    (including its employees who, subsequent to the first
                    disclosure of Confidential Information, become former
                    employees);

               (b)  That the Receiving Party shall not, directly or indirectly,
                    disclose or use the Confidential Information, in whole or in
                    part, for any purposes other than those contemplated herein.
                    Without affecting the generality of the foregoing, the
                    Receiving Party shall not, directly or indirectly, disclose
                    any such Confidential Information to any third party or use
                    the Confidential Information for the benefit of any third
                    party;

               (c)  That neither party shall, without the prior written consent
                    of the other party, disclose to any third party the fact
                    that the Confidential Information has been made available or
                    any of the terms, conditions or other facts with respect to
                    the business relationship of the parties. Any disclosure
                    made shall be no more extensive than is necessary to meet
                    the minimum requirement imposed on the party making such
                    disclosure;

               (d)  That money damages would not be a sufficient remedy for a
                    breach of this Article 8 and that the non-breaching party
                    shall be entitled to equitable relief (including, but not
                    limited to, an injunction or specific performance) in the
                    event of any breach of the provisions of this Article 8;

               (e)  The furnishing of Confidential Information hereunder shall
                    not constitute or be construed as a grant of any express or
                    implied license or other right, or a covenant not to sue or
                    forbearance form any other right of action by the Disclosing
                    Party to the Receiving Party under any of the Disclosing
                    Party's patents or other intellectual property rights;

               (f)  Upon the Disclosing Party's request, upon termination or
                    expiration of this Agreement, the Receiving Party shall
                    immediately return all written, graphic and other tangible
                    forms of the Confidential Information (and all copies
                    thereof) in the Receiving Party's possession or control
                    except for one copy which may be retained for legal archival
                    purposes; and

               (g)  The obligations of the Receiving Party regarding disclosure
                    and use of Confidential Information shall survive the
                    termination of this Agreement and shall continue for ten
                    (10) years after the date of termination of this Agreement.

                                  9. PUBLICITY

         9.1.  During the Term and thereafter, except as required by applicable
               law, neither party shall, without securing the prior written
               consent of the other party, release publicly the terms of this
               Agreement to any third party or publicly announce the terms of
               this Agreement. During the Term and thereafter, either party may
               use the name of the other party in press releases, shareholder
               reports, quarterly and annual corporate reports, SEC filings and
               public or private stock offerings and in connection with its
               marketing activities related to the Product, provided however
               that each party shall give the other five business days to review
               and comment on written material related to the other party.

                                        9

<PAGE>

                       10. WARRANTIES AND REPRESENTATIONS

         10.1. OraPharma warrants and represents that it will not, to the best
               of its knowledge, sell, either directly or indirectly, or through
               its Sub-distributors, any Product for use outside the scope of
               this Agreement.

         10.2. OraPharma warrants that it shall comply with all applicable laws
               and governmental authorities and governmental approvals affecting
               the use, possession, distribution, labeling, advertising and all
               forms of promotion in connection with the sale and distribution
               of the Product.

         10.3. KNC warrants that it has received Section 510(k) clearance and
               class III pre-market approvals from the U.S. Food and Drug
               Administration to market Epi-Guide(R) bioresorbable periodontal
               matrix barrier and Drilac(R) polylactic acid surgical dressing,
               respectively, in the U.S. in accordance with the provisions of
               the U.S. Federal Food, Drug and Cosmetic Act and has received
               full regulatory approval to market and sell Epi-Guide(R) and
               Drilac(R) in Canada.

         10.4. KNC warrants that it shall provide OraPharma with Product which
               meets the Product Specifications and is manufactured at
               facilities registered with the FDA, to the extent required by
               law, and in accordance with applicable government requirements
               and all applicable laws, rules and regulations of each
               governmental agency having jurisdiction over the manufacture and
               sale of Product in accordance with the provisions of this
               Agreement, and which is of reasonable commercial quality, fit for
               the purpose intended.

         10.5. KNC represents and warrants that it is the owner of all right,
               title and interest to the Product, and that the use, sale, and/or
               import of Product does not infringe any intellectual property
               right, including but not limited to copyright, or patent of any
               third party.

         10.6. In the event of a warranty claim by an end-user of the Product,
               such as a manufacturing defect or missing part, OraPharma is
               hereby authorized to accept on KNC's behalf such Product returns,
               whereby KNC will refund or credit to OraPharma the purchase price
               for all defective Product, including the freight costs incurred
               by OraPharma.

         10.7. KNC and OraPharma each represent and warrant for itself that (i)
               it has the full right, power, and authority to execute and
               perform this Agreement and to grant the rights as provided
               herein, and (ii) this Agreement does not conflict with or
               otherwise result in a breach of any agreement to which such party
               is a party or to which it is bound.

         10.8. EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN THIS ARTICLE 10,
               NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
               EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY
               OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR A PARTICULAR
               PURPOSE.

                                       10

<PAGE>

                            11. GOVERNMENT APPROVALS

         11.1. It will be the sole responsibility and right of OraPharma, at
               OraPharma's sole cost and expense, to seek, prepare, file and
               prosecute all governmental applications necessary to obtain
               approvals to export, advertise, promote, market, distribute and
               sell the Product in the Field in the Territory ("Government
               Approvals"). KNC shall cooperate with OraPharma in the
               prosecution of all Government Approvals.

         11.2. Notwithstanding the provisions of Section 11.1, KNC owns U.S.
               Food and Drug Administration clearance K940643, PMA P800012 and
               Canadian approvals prosecuted by KNC and will maintain such
               approvals at its sole expense.

                        12. RESERVATION OF RIGHTS BY KNC

         12.1. KNC reserves all rights and products not expressly, specifically
               and exclusively conveyed upon OraPharma hereunder.

                                 13. ASSIGNMENT

         13.1. Neither party may assign or transfer this Agreement, in whole or
               in part, to a third party without the prior written consent of
               the other party, which consent shall not be unreasonably
               withheld.

         13.2. This Agreement will bind and inure to the benefit of the
               respective successors and permitted assigns, whether so expressed
               or not.

                                 14. INSURANCE

         14.1. KNC and OraPharma shall each obtain and maintain at all times
               during the Term, product liability insurance in the amount of at
               least [***] and shall deliver to the other party a certificate
               evidencing such insurance, which names the other party as an
               additional insured.

                                 15. TERMINATION

         15.1. (a)  KNC shall have the right, but not the obligation, to
               terminate this Agreement upon sixty (60) days written notice by
               certified mail to OraPharma under the following circumstances,
               unless the circumstances are remedied or cured within said sixty
               (60) day notice period:

               (1)  if any amounts due KNC are unpaid;

               (2)  if OraPharma declares bankruptcy, OraPharma makes an
                    assignment for the benefit of its creditors, if any
                    proceedings take place for reorganization or arrangement for
                    the appointment of a receiver or trustee to take possession
                    of OraPharma's assets, or any other proceeding under law for
                    the relief of creditors shall be instituted;

[***] Confidential treatment requested

                                       11

<PAGE>

               (3)  if OraPharma fails to purchase Minimum Purchase Guarantees
                    as provided in Section 4.2.; or

               (4)  if OraPharma materially breaches its obligations under this
                    Agreement.

         (b)   OraPharma shall have the right, but not the obligation, to
               terminate this Agreement upon sixty (60) days written notice by
               certified mail to KNC under the following circumstances, unless
               the circumstances are remedied or cured within said sixty (60)
               day notice period:

               (1)  if KNC is unable to supply OraPharma with commercially
                    reasonable quantities of Product for a period in excess of
                    six months, if requested amounts do not exceed forecasted
                    quantities;

               (2)  if KNC declares bankruptcy, KNC makes an assignment for the
                    benefit of its creditors, if any proceedings take place for
                    reorganization or arrangement for the appointment of a
                    receiver or trustee to take possession of KNC's assets, or
                    any other proceeding under law for the relief of creditors
                    shall be instituted;

               (3)  if KNC materially breaches its obligations under this
                    Agreement; or

               (4)  if OraPharma is unable, after commercially reasonable
                    efforts, to obtain any Government Approval in all or part of
                    the Territory.

         15.2. Upon termination of this Agreement for any reason, including the
               end of the Term as defined in Section 2.6, nothing herein shall
               be construed to release either party from any obligation which
               matured prior to the Effective Date of termination including, but
               not limited to, Minimum Purchase Guarantees as defined in Section
               4.2.

         15.3. Upon termination of this Agreement for any reason, including the
               end of the Term as defined in Section 2.6, OraPharma shall
               immediately and permanently discontinue all use of the Marks, as
               well as any name, trademark, trade name slogan, title, label, or
               anything else that would be likely to lead to confusion or make
               it appear that OraPharma is the authorized distributor of the
               Product. KNC shall have the option to purchase from OraPharma all
               government or health authority approvals to market the Product
               for an amount to be negotiated in good faith between KNC and
               OraPharma.

         15.4. Upon termination of this Agreement for any reason, including the
               end of the Term as defined in Section 2.6, OraPharma shall notify
               its customers and others that it has ceased to be a distributor.
               KNC shall have the option exercisable by written notice to
               OraPharma within thirty days of termination or expiration to
               repurchase all OraPharma's stocks of Product on hand at the
               effective date of termination or expiration which are in good and
               saleable condition at OraPharma's landed cost thereof. Absent
               receipt of such notice, and solely if the termination is pursuant
               to Section 15.1(b), OraPharma shall be permitted to continue to
               sell Product in the Territory until OraPharma's stocks of Product
               are exhausted or the expiration of a period of six (6) months
               following the effective date of termination, whichever is
               earlier, during such corresponding time, Section 15.3 shall be
               waived.

                                       12

<PAGE>

                               16. INDEMNIFICATION

         16.1. KNC agrees to indemnify, defend and hold OraPharma and any of its
               officers, directors, affiliates, Sub-distributors, employees,
               sales agents, successors and permitted assigns harmless from any
               and all damages (including, without limitation, amounts paid by
               OraPharma in judgement or in settlement with KNC's consent)
               losses, claims, demands, liabilities, cost and expenses
               (including, without limitation, reasonable court costs and
               attorney's fees) incident or relating to, based upon or rising
               out of any claim, demand, cause of action, suit or proceeding
               resulting from KNC's manufacturing, testing, design, qualifying,
               preparing for shipping, and packaging of Product or actions not
               in accord with this Agreement, except for such claims which arise
               out of or result from the negligence, gross negligence or willful
               misconduct of OraPharma, or are otherwise subject to
               indemnification under Section 16.2.

         16.2. OraPharma agrees to indemnify, defend and hold KNC and any of its
               officers, directors, affiliates, employees, sales agents,
               successors and permitted assigns harmless from any and all
               damages (including, without limitation, amounts paid by KNC in
               judgement or in settlement with OraPharma's consent) losses,
               claims, demands, liabilities, cost and expenses (including,
               without limitation reasonably court costs and attorney's fees)
               incident or relating to, based upon or arising out of any claim,
               demand, cause of action, suit or proceeding resulting from
               OraPharma's advertising, promoting, marketing, distributing and
               selling of Product or actions not in accord with this Agreement,
               except for such claims which arise out of or result from the
               negligence, gross negligence or willful misconduct of KNC, or are
               otherwise subject to indemnification under Section 16.1.

                          17. MISCELLANEOUS PROVISIONS

         17.1. Independent Contractor. Neither party shall have the right, power
               or authority to assume or create any obligations or
               responsibility expressed or implied, on behalf of, or in the name
               of, the other party, or to bind the other party in any manner or
               to any extent whatsoever, without the prior written approval and
               acceptance of the other party. Each of the parties hereto is an
               independent contractor for the purposes of this Agreement and
               nothing contained herein shall be deemed or construed to create
               the relationship of agency, partnership or joint venture or any
               other association except that of an independent contractor
               relationship.

         17.2. Amendment and Waiver. This Agreement may be amended, and any
               provision of this Agreement may be waived, provided that any such
               amendment or waiver will be binding on each party only if such
               amendment or waiver is set forth in a writing executed by such
               parties. Waiver of a breach of the Agreement shall not constitute
               a waiver of any other subsequent breach of the Agreement. The
               waiver of any provision of this Agreement shall not constitute a
               continuing waiver of that provision or a waiver of any other
               provision of this Agreement.

                                       13

<PAGE>

         17.3. Notices. All notices, demands and other communications to be
               given or delivered under or by reason of the provisions of this
               Agreement will be in writing and will be deemed to have been
               given when personally delivered or mailed by overnight mail,
               return receipt requested. Notices, demands and communications
               will, unless another address is specified in writing, be sent to
               the addresses set forth as follows:

                        If to OraPharma:              Michael D. Kishbauch
                                                      President and CEO
                                                      OraPharma, Inc.
                                                      732 Louis Drive
                                                      Warminster, PA  18974

                        If to KNC:                    Joseph W. Kaufmann
                                                      President and CEO
                                                      Kensey Nash Corporation
                                                      55 East Uwchlan Avenue
                                                      Exton, PA  19341

         17.4. Severability. Whenever possible, each provision of this Agreement
               will be interpreted in such a manner as to be effective and valid
               under applicable law, but if any provision of this Agreement is
               held to be prohibited by or invalid under applicable law, such
               provision will be ineffective only to the extent of such
               prohibition or invalidity, without invalidating the remainder of
               such provision or the remaining provisions of this Agreement.

         17.5. Complete Agreement. This document and the documents referred to
               herein contain the complete agreement between the parties and
               supersede all prior understandings, agreements and
               representations by or between the parties, written or oral, which
               may have related to the subject matter hereof in any way.

         17.6. Counterparts. This Agreement may be executed in one or more
               counterparts all of which taken together will constitute one and
               the same instrument.

         17.7. Governing Law. The law of the Commonwealth of Pennsylvania will
               govern, without regard to the conflicts of law provisions
               thereof, all questions concerning the construction, validity and
               interpretation of this Agreement and the performance of the
               obligations imposed by this Agreement.

         17.8. Headings. Section headings used in this Agreement are for
               convenience only and form no part or in any way modify or define
               the text of meaning or any provision of this Agreement.

         17.9. Force Majeure. Neither party shall be liable or deemed in default
               for failure to perform any duty or obligation that such party may
               have under this Agreement where such failure has been directly or
               indirectly caused by any act of God, fire, strike, inevitable
               accident, war, or any other cause outside the reasonable control
               of that party, and occurring without its fault or negligence. The
               party whose performance has been so interrupted shall give the
               other party prompt notice of the interruption and the cause

                                       14

<PAGE>

                thereof, and shall use its best efforts to resume full
                performance of this Agreement as soon as possible.

         17.10. Damage Exclusions. EXCEPT AS OTHERWISE PROVIDED ELSEWHERE IN
                THIS AGREEMENT, NONE OF THE PARTIES SHALL BE LIABLE TO THE OTHER
                FOR ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL OR SPECIAL DAMAGES
                OR LOST SALES OR PROFITS IN CONNECTION WITH ANY MATTERS RELATING
                IN ANY MANNER TO THIS AGREEMENT OR OTHERWISE RELATING TO THE
                BUSINESS RELATIONSHIP OF THE PARTIES, EVEN IF SUCH PARTY HAS
                BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES BY THE OTHER
                PARTIES.

         17.11. U.S. Export Restrictions. OraPharma acknowledges that KNC and
                all related technical information, documents and materials are
                subject to export controls under the U.S. Export Administration
                Regulations. OraPharma will (i) comply strictly with all legal
                requirements established under these controls, (ii) cooperate
                fully with KNC in any official or unofficial audit or inspection
                that relates to these controls, and (iii) not export, re-export,
                direct or transfer, directly or indirectly, the Product to any
                country or nation therefor that is embargoed by executive order,
                unless OraPharma has obtained the prior written authorization of
                KNC and the U.S. Commerce Department.

IN WITNESS WHEREOF, the parties have executed this Agreement through their duly
authorized representatives as of the date first written above.

ORAPHARMA, INC                                 KENSEY NASH CORPORATION

By:  _________________________________         By:  ____________________________
Michael D. Kishbauch                                 Joseph W. Kaufmann
President and CEO                                    President & CEO

                                       15

<PAGE>

                      Schedule A ("Product Specifications")

                                      [***]

_______

[***] Confidential treatment requested

<PAGE>

                         Schedule B ("Product Drawings")

                             [Picture appears here]

<PAGE>

              Schedule C ("Minimum Purchase Guarantee of Product")

Initial Term - Epi-Guide(R)Bioresorbable Barrier Matrix

[***]

Initial Term - Drilac(R)Polylactic Acid OPLA Surgical Dressing

[***]

_______

[***] Confidential treatment requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]